Evidence map›Paper›PMID 37867955›Full record

ArticleiScience2023

AI diagnosis of Bethesda category IV thyroid nodules.

Jincao Yao, Yanming Zhang, Jiafei Shen, Zhikai Lei, Jing Xiong, Bojian Feng, Xiaoxian Li, Wei Li, Di Ou, Yidan Lu and 10 more

Open access · goldAbstract read
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 4 pooled it
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 2 countries.

Jincao YaoDepartment of Ultrasound, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Yanming ZhangZhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China.
Jiafei ShenDepartment of Ultrasound, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Zhikai LeiZhejiang University School of Medicine, Affiliated Hangzhou First People's Hospital, Hangzhou 310003, China.
Jing XiongShenzhen Institute of Advanced Technology, Chinese Academy of Sciences, 518055, China.
Bojian FengDepartment of Ultrasound, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Xiaoxian LiDepartment of Ultrasound, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
Wei LiDepartment of Ultrasound, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Di OuDepartment of Ultrasound, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Yidan LuDepartment of Ultrasound, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Na FengDepartment of Ultrasound, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Meiying YanDepartment of Ultrasound, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Jinjie ChenDepartment of Statistical Science, Baylor University, Waco, TX 76706, USA.
Liyu ChenDepartment of Ultrasound, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Chen YangDepartment of Ultrasound, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Liping WangDepartment of Ultrasound, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Kai WangDepartment of Ultrasound, The Affiliated Dongyang Hospital of Wenzhou Medical University, Dongyang 322100, China.
Jianhua ZhouDepartment of Ultrasound, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
Ping LiangDepartment of Ultrasound, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing 100853, China.
Dong XuDepartment of Ultrasound, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Chinese Academy of Sciences · CNSun Yat-sen University · CNBaylor University · USChinese PLA General Hospital · CNHangzhou First People's Hospital · CNWenzhou Medical University · CNZhejiang Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid nodules are a common disease, and fine needle aspiration cytology (FNAC) is the primary method to assess their malignancy. For the diagnosis of follicular thyroid nodules, however, FNAC has limitations. FNAC can classify them only as Bethesda IV nodules, leaving their exact malignant status and pathological type undetermined. This imprecise diagnosis creates difficulties in selecting the follow-up treatment. In this retrospective study, we collected ultrasound (US) image data of Bethesda IV thyroid nodules from 2006 to 2022 from five hospitals. Then, US image-based artificial intelligence (AI) models were trained to identify the specific category of Bethesda IV thyroid nodules. We tested the models using two independent datasets, and the best AI model achieved an area under the curve (AUC) between 0.90 and 0.95, demonstrating its potential value for clinical application. Our research findings indicate that AI could change the diagnosis and management process of Bethesda IV thyroid nodules.

Indexed as

cancermedical imagingneural networks

Identifiers

PMID37867955
PMCPMC10589877
OpenAlexW4387340467

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.